Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Ning Li et al.|Journal of Thoracic Oncology|2020Cited by 415
Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in ChinaFei Wang, Jie He, Chao Qin et al.|American Journal of Respiratory and Critical Care Medicine|2022Cited by 71
Lung cancer risk prediction models based on pulmonary nodules: A systematic reviewZheng Wu, Jie He, Fei Wang et al.|Thoracic Cancer|2022Cited by 56
Uptake of lung cancer screening with low-dose computed tomography in China: A multi-centre population-based studyWei Cao, Jie He, Fengwei Tan et al.|EClinicalMedicine|2022Cited by 32
Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.Shugeng Gao, Jie He, Ning Li et al.|Journal of Clinical Oncology|2021Cited by 5